Redeye comments on AlzeCure Pharma’s signing of a landmark global out-licensing and collaboration agreement with Danish biotech QuantumCell ApS for the NeuroRestore platform, including its Phase II clinical lead asset ACD856, in a blockbuster deal worth up to USD2.2 billion.
LÄS MER
